FDA approves GSK’s Jideytro for previously treated ROS1-positive NSCLC

GlaxoSmithKline plc Sponsored ADR

GlaxoSmithKline plc Sponsored ADR

GSK

0.00
  • FDA cleared GSK’s Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive NSCLC previously treated with a ROS1 inhibitor.
  • Green light came ahead of the Sept. 18, 2026, target action date.
  • Approval backed by ARROS-1 data showing a 44% objective response rate in 117 patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.